Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial.

Venugopal MenonA Michael LincoffStephen J NichollsSusan JasperKathy WolskiDarren K McGuireCyrus R MehtaJulio RosenstockClaudia LopezJohn MarcinakCharlie CaoSteven E Nissennull null

Published in: Diabetes care (2019)

Development of fasiglifam was terminated due to concerns of drug-induced liver injury. Performance of a U.S. Food and Drug Administration-mandated CV outcomes trial supported the termination of the fasiglifam clinical program.

Keyphrases

drug administration
phase iii
study protocol
phase ii
clinical trial
quality improvement
randomized controlled trial
open label
emergency department
type diabetes
metabolic syndrome
human health
weight loss
climate change
skeletal muscle
adipose tissue
glycemic control